Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! View ALL results for your Stocks, ETFs and Funds Screeners with Barchart Plus. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | More
 
or
Watchlist | Portfolio
Site News
Contact
Market:

Foghorn Therapeutics Inc (FHTX)

Foghorn Therapeutics Inc (FHTX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Flagship Pioneering Announces the Merger of Two Leading Programmable Medicine Platforms to Form Sail Biomedicines PR Newswire - Thu Oct 19, 2023

/PRNewswire/ -- Flagship Pioneering today announced the combination of Laronde and Senda Biosciences to launch Sail Biomedicines, a company pioneering the...

DNLI : 15.43 (+3.14%)
FHTX : 5.49 (+4.97%)
MRNA : 107.97 (+1.69%)
OMGA : 2.27 (-3.40%)
SANA : 8.72 (+2.59%)
MCRB : 0.8250 (+11.08%)
Flagship Pioneering Appoints John Lepore as CEO-Partner and CEO of ProFound Therapeutics PR Newswire - Mon Oct 2, 2023

/PRNewswire/ -- Flagship Pioneering, the bioplatform innovation company, and ProFound™ Therapeutics, a company pioneering the discovery of a vastly expanded...

DNLI : 15.43 (+3.14%)
FHTX : 5.49 (+4.97%)
MRNA : 107.97 (+1.69%)
OMGA : 2.27 (-3.40%)
SANA : 8.72 (+2.59%)
MCRB : 0.8250 (+11.08%)
Flagship Pioneering Named to Fortune's 2023 "Change the World" List PR Newswire - Wed Sep 27, 2023

/PRNewswire/ -- Flagship Pioneering today announced it has been named to FORTUNE's 2023 "Change the World" list, an annual global ranking of companies that...

DNLI : 15.43 (+3.14%)
FHTX : 5.49 (+4.97%)
MRNA : 107.97 (+1.69%)
OMGA : 2.27 (-3.40%)
SANA : 8.72 (+2.59%)
MCRB : 0.8250 (+11.08%)
Flagship Pioneering Announces Appointment of Amanda Kay as Chief Business Development Officer PR Newswire - Mon Sep 11, 2023

/PRNewswire/ -- Flagship Pioneering, the bioplatform innovation company, announced today the appointment of Amanda Kay as Senior Partner and Chief Business...

DNLI : 15.43 (+3.14%)
FHTX : 5.49 (+4.97%)
MRNA : 107.97 (+1.69%)
OMGA : 2.27 (-3.40%)
SANA : 8.72 (+2.59%)
MCRB : 0.8250 (+11.08%)
Flagship Pioneering Announces Appointment of David Khougazian as Growth Partner PR Newswire - Tue Aug 29, 2023

/PRNewswire/ -- Flagship Pioneering, the bioplatform innovation company, announced today that pharma and healthcare leader David Khougazian is joining as...

DNLI : 15.43 (+3.14%)
FHTX : 5.49 (+4.97%)
MRNA : 107.97 (+1.69%)
OMGA : 2.27 (-3.40%)
SANA : 8.72 (+2.59%)
MCRB : 0.8250 (+11.08%)
Flagship Pioneering Appoints Jason Gardner as CEO-Partner and CEO of Ampersand Biomedicines PR Newswire - Mon Aug 14, 2023

/PRNewswire/ -- Flagship Pioneering, the bioplatform innovation company, and Ampersand Biomedicines, a company programming smarter medicines that act...

DNLI : 15.43 (+3.14%)
FHTX : 5.49 (+4.97%)
MRNA : 107.97 (+1.69%)
OMGA : 2.27 (-3.40%)
SANA : 8.72 (+2.59%)
MCRB : 0.8250 (+11.08%)
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Foghorn Therapeutics Inc. - FHTX PR Newswire - Wed May 10, 2023

/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Foghorn Therapeutics Inc. ("Foghorn" or the "Company") (NASDAQ: FHTX). Such...

FHTX : 5.49 (+4.97%)
Foghorn Therapeutics Inc. (FHTX) Reports Q1 Loss, Lags Revenue Estimates Zacks - Mon May 8, 2023

Foghorn Therapeutics Inc. (FHTX) delivered earnings and revenue surprises of -7.35% and 12.88%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?...

FHTX : 5.49 (+4.97%)
PRPH : 4.71 (-4.85%)
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Foghorn Therapeutics Inc. - FHTX PR Newswire - Tue May 2, 2023

/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Foghorn Therapeutics Inc. ("Foghorn" or the "Company") (NASDAQ: FHTX). Such...

FHTX : 5.49 (+4.97%)
Foghorn Therapeutics Inc. (FHTX) Soars 13.1%: Is Further Upside Left in the Stock? Zacks - Thu Apr 27, 2023

Foghorn Therapeutics Inc. (FHTX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength...

FHTX : 5.49 (+4.97%)
ACRS : 1.2000 (+0.84%)

Barchart Exclusives

FOMC, Earnings and Other Can't Miss Items This Week Barchart - Sun Apr 28, 2:00PM CDT
This week's earnings are still a strong theme and in addition Non-Farm Payrolls, JOLTs, and the big one, The Fed Funds rate. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar

[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot